VSTM

Verastem, Inc. [VSTM] Stock Forecast

Buy or Sell ? Support and Resistance

What is MACD and how to read it?

How RSI can help?
RSI : 000

VSTM Stock Summary

Top 10 Correlated ETFs

VSTM


Top 10 Correlated Stocks

VSTM


In the News

07:15 29 Mar 2024 VSTM

3 Stocks That AI Predicts Will Deliver Triple-Digit Returns This Year: February 2024

In the vast landscape of today's markets, artificial intelligence (AI) is reshaping investment strategies. Therefore, AI stock picks are as relevant as ever.

01:01 29 Mar 2024 VSTM

Verastem: Other Catalysts In 2024 Beyond NDA Rolling Submission Of Defactinib

Rolling NDA submission of avutometinib + defactinib for the treatment of patients with low-grade serous ovarian cancer is expected in the 1st half of 2024, with possible commercialization in 2025. Results from two studies, RAMP-203 and RAMP-204, each using avutometinib with two different types of KRAS G12C inhibitors for the treatment of KRAS G12C NSCLC, expected mid-2024. The global non-small cell lung cancer market is expected to reach $38.8 billion by 2030; About 13% of NSCLC patients have the KRAS G12C mutation.

09:16 29 Mar 2024 VSTM

Verastem (VSTM) Up 8% on Fast Track Tag for NSCLC Combo Therapy

Verastem's (VSTM) avutometinib/Lumakras combination therapy gets the FDA's Fast Track designation to treat KRAS G12C-mutant metastatic NSCLC patients. The stock gains 8% in response.

09:08 29 Mar 2024 VSTM

3 Off-the-Beaten-Path Stocks Poised for Substantial Growth

As horror film fans know, there's safety in numbers but robust profitability may be more closer to the domain of uncommon stocks to buy for growth. Don't get me wrong – if you find yourself facing the market equivalent of a hockey-mask-wearing villain, you should probably consider the tried-and-true strength-in-numbers narrative.

04:17 29 Mar 2024 VSTM

Small Stakes, Big Rewards: 3 Penny Stocks with 300% Upside Potential

If the first rule in the film “Fight Club” is to not talk about fight club, then the same rule applies to penny stocks with potential: you do not talk about these penny stocks with upside. To clarify, the ideas present tremendous risks.

02:22 29 Mar 2024 VSTM

3 Penny Stocks to Buy to Turn $1 into $100: November 2023

In this market cycle that we are experiencing, new opportunities arise to take advantage of over the next few years. There is no better way to take advantage of these opportunities than through penny stocks.

01:32 29 Mar 2024 VSTM

All You Need to Know About Verastem (VSTM) Rating Upgrade to Buy

Verastem (VSTM) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

01:40 29 Mar 2024 VSTM

Verastem: Potential Accelerated Approval Filing In H1 2024

An application for Accelerated Approval of avutometinib + defactinib for low-grade serous ovarian cancer patients is expected in the first half of 2024. The ongoing RAMP-301 study is being done to keep avutometinib + defactinib for LGSC on the market or to convert Accelerated Approval to Full Approval. Company entered into a collaboration agreement with GenFleet Therapeutics to expand its pipeline and strengthen its position in the RAS driven cancer pathway space.

09:00 29 Mar 2024 VSTM

Verastem: Signs Of Life For A Beaten-Down Equity

Verastem is a biotechnology company focused on developing novel agents for solid tumors, with its main candidate being avutometinib. Avutometinib is being studied in various cancers, driven by RAS pathway activation, with promising early results in relapsed/refractory low-grade serous ovarian carcinoma. Verastem has sufficient cash to reach a new milestone in 2024 or early 2025, but more data is needed to determine if avutometinib is a viable solution in solid tumor oncology.

07:00 29 Mar 2024 VSTM

Verastem Oncology to Participate in Upcoming Investor Conferences

BOSTON--(BUSINESS WIRE)--Verastem Oncology, (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today announced that the Company will participate in the following upcoming investor conferences: H.C. Wainwright 25th Annual Global Investment Conference; podium presentation on Tuesday, September 12, 2023 at 2:00 p.m. ET 2023 Cantor Global Healthcare Conference; fireside chat on Tuesday, September 26, 2023 at 9:55 a.m. ET A live webcast of the.

VSTM Financial details

Company Rating
Neutral
Market Cap
304.56M
Income
-84.51M
Revenue
0
Book val./share
2.93
Cash/share
5.15
Dividend
-
Dividend %
-
Employees
73
Optionable
No
Shortable
Yes
Earnings
07 May 2024
P/E
-3.62
Forward P/E
-4.15
PEG
2.47
P/S
97.33
P/B
2.57
P/C
2.3
P/FCF
-3.44
Quick Ratio
6.96
Current Ratio
7.33
Debt / Equity
0.52
LT Debt / Equity
0.51
-
-
EPS (TTM)
-3.91
EPS next Y
-2.86
EPS next Q
-1.05
EPS this Y
-13.54%
EPS next Y
-26.94%
EPS next 5Y
-188.24%
EPS last 5Y
-31.99%
Revenue last 5Y
-100%
Revenue Q/Q
-
EPS Q/Q
36%
-
-
-
-
SMA20
-7.69%
SMA50
9.09%
SMA100
100%
Inst Own
0.01%
Inst Trans
0%
ROA
-42%
ROE
-90%
ROC
-0.51%
Gross Margin
100%
Oper. Margin
-2997%
Profit Margin
-2849%
Payout
-
Shs Outstand
25.3M
Shs Float
20.47M
-
-
-
-
Target Price
5
52W Range
4.2-15.12
52W High
-20.93%
52W Low
+196.5%
RSI
53
Rel Volume
0.38
Avg Volume
147.9K
Volume
56.09K
Perf Week
0.59%
Perf Month
1.02%
Perf Quarter
48.06%
Perf Half Y
26.57%
-
-
-
-
Beta
0.487
-
-
Volatility
0.17%, 0.74%
Prev Close
0.34%
Price
11.86
Change
0.76%

VSTM Financial Performance

Yearly Fundamentals Overview

Last date of statement is 2023-12-31

Metric History 2019-12-312020-12-312021-12-312022-12-31 2023-12-31
2.02K2.02K2.02K2.02K2.02K
Revenue per share
2.816.930.140.160
Net income per share
-27.22-5.3-5.58-4.58-3.96
Operating cash flow per share
-22.29-2.62-3.68-3.95-3.92
Free cash flow per share
-22.29-2.62-3.69-3.95-3.92
Cash per share
12.1511.0512.335.456.26
Book value per share
1.159.026.022.943.56
Tangible book value per share
-2.079.026.022.943.56
Share holders equity per share
1.159.026.022.943.56
Interest debt per share
20.6230.891.812.05
Market cap
99.93M326.59M357.53M77.46M179.52M
Enterprise value
163.95M281.35M259.54M29.59M142.24M
P/E ratio
-0.59-4.82-4.41-1.05-2.05
Price to sales ratio
5.723.69174.1529.840
POCF ratio
-0.72-9.75-6.68-1.22-2.08
PFCF ratio
-0.72-9.74-6.66-1.22-2.08
P/B Ratio
13.932.834.081.632.29
PTB ratio
13.932.834.081.632.29
EV to sales
9.393.18126.4211.40
Enterprise value over EBITDA
-1.3-5.91-4.24-0.41-1.55
EV to operating cash flow
-1.18-8.4-4.85-0.46-1.65
EV to free cash flow
-1.18-8.39-4.83-0.46-1.65
Earnings yield
-1.69-0.21-0.23-0.95-0.49
Free cash flow yield
-1.39-0.1-0.15-0.82-0.48
Debt to equity
14.990.20.030.570.52
Debt to assets
0.740.150.030.280.27
Net debt to EBITDA
-0.510.951.60.670.41
Current ratio
2.848.485.694.295.45
Interest coverage
-6.42-3.13-6.16-34.13-22.25
Income quality
0.930.490.750.860.99
Dividend Yield
00000
Payout ratio
00000
Sales general and administrative to revenue
00000
Research and developement to revenue
2.620.4719.1719.480
Intangibles to total assets
0.140000
Capex to operating cash flow
00000
Capex to revenue
00-0.100
Capex to depreciation
0-0.03-2.7200.11
Stock based compensation to revenue
0.490.093.762.330
Graham number
26.5932.827.517.3917.82
ROIC
-1.27-0.35-0.75-0.95-0.77
Return on tangible assets
-1.35-0.44-0.75-0.78-0.58
Graham Net
-9.488.017.442.493.03
Working capital
55.07M127.85M87.15M71.21M117.3M
Tangible asset value
-12.83M115.27M87.56M47.39M78.53M
Net current asset value
-52.91M105.86M84.64M45.21M72.5M
Invested capital
14.990.20.030.570.52
Average receivables
1.42M1.38M377.5K273.5K36.5K
Average payables
9.95M5.77M2.09M3.6M6.04M
Average inventory
1.71M1.55M-50.39M-50.39M0
Days sales outstanding
52.780.9991.744.360
Days payables outstanding
1.26K20.284.08K15.16K42.29K
Days of inventory on hand
402.580-178.55K00
Receivables turnover
6.92370.363.9883.740
Payables turnover
0.29180.090.020.01
Inventory turnover
0.910000
ROE
-23.58-0.59-0.93-1.56-1.11
Capex per share
00-0.0100

Quarterly Fundamentals Overview

Last date of statement is 2023-12-31 for Q4

Metric History 2022-12-312023-03-312023-06-302023-09-30 2023-12-31
2.02K2.02K2.02K2.02K2.02K
Revenue per share
0.150000
Net income per share
-0.99-0.77-1.37-0.75-1.02
Operating cash flow per share
-0.98-1.21-1.12-0.62-1.11
Free cash flow per share
-0.98-1.21-1.12-0.62-1.11
Cash per share
5.166.6510.336.185.15
Book value per share
2.783.246.923.892.93
Tangible book value per share
2.783.246.923.892.93
Share holders equity per share
2.783.246.923.892.93
Interest debt per share
1.632.612.461.611.57
Market cap
81.8M84.29M131.93M217.8M218.22M
Enterprise value
33.93M29.96M-8.66M164.85M180.94M
P/E ratio
-1.22-1.64-1.36-2.72-1.99
Price to sales ratio
31.510000
POCF ratio
-4.92-4.15-6.63-13.13-7.35
PFCF ratio
-4.92-4.15-6.63-13.13-7.35
P/B Ratio
1.731.561.072.092.78
PTB ratio
1.731.561.072.092.78
EV to sales
13.070000
Enterprise value over EBITDA
-2.11-20.37-8.73-5.81
EV to operating cash flow
-2.04-1.480.44-9.94-6.1
EV to free cash flow
-2.04-1.480.44-9.94-6.1
Earnings yield
-0.21-0.15-0.18-0.09-0.13
Free cash flow yield
-0.2-0.24-0.15-0.08-0.14
Debt to equity
0.570.790.350.40.52
Debt to assets
0.280.360.220.240.27
Net debt to EBITDA
2.983.636.072.811.2
Current ratio
4.295.329.147.335.45
Interest coverage
-23.27-25.15-18.1-18.87-27.8
Income quality
0.991.290.820.831.08
Dividend Yield
00000
Payout ratio
00000
Sales general and administrative to revenue
00000
Research and developement to revenue
4.140000
Intangibles to total assets
00000
Capex to operating cash flow
00000
Capex to revenue
00000
Capex to depreciation
00000
Stock based compensation to revenue
0.50000
Graham number
7.867.4914.68.098.2
ROIC
-0.22-0.16-0.11-0.15-0.26
Return on tangible assets
-0.18-0.11-0.13-0.11-0.18
Graham Net
2.362.666.433.52.5
Working capital
71.21M96.53M169.18M150.67M117.3M
Tangible asset value
47.39M54.18M122.75M104.34M78.53M
Net current asset value
45.21M52.2M120.96M102.67M72.5M
Invested capital
0.570.790.350.40.52
Average receivables
52.5K46.5K32K22K42K
Average payables
5.13M4.9M4.73M4.84M6.15M
Average inventory
0-31K-31K-21K-21K
Days sales outstanding
1.070000
Days payables outstanding
15.21K14.71K18.63K92.12K129.31K
Days of inventory on hand
0-1860-7560
Receivables turnover
83.740000
Payables turnover
0.010.01000
Inventory turnover
0-0.480-0.120
ROE
-0.35-0.24-0.2-0.19-0.35
Capex per share
00000

VSTM Frequently Asked Questions

What is Verastem, Inc. stock symbol ?

Verastem, Inc. is a US stock , located in Needham of Ma and trading under the symbol VSTM

Is Verastem, Inc. buy or a sell ?

1 stock analysts have 1 predictions with a medium analyst target price of $5. The lowest prediction is $5 and the highest is $5

What is VSTM stock prediction ?

What is Verastem, Inc. stock quote today ?

Verastem, Inc. stock price is $11.86 today.

Is Verastem, Inc. stock public?

Yes, Verastem, Inc. is a publicly traded company.

Something similar

Top by Market Cap
Top Correlated ETFs
Top Correlated Stocks
Similar Market Cap